Hormone Insight Editorial Team

PICO GLP-1 Receptor Agonists Dec 28, 2024

SELECT Kidney Outcomes

PICO Heart Failure & Renal Protection Dec 28, 2024

STEP-HFpEF: Semaglutide Improves NYHA Functional Class in Obesity-Related HFpEF

PICO GLP-1 Receptor Agonists Dec 28, 2024

Semaglutide and Kidney Outcomes

PICO Heart Failure & Renal Protection Dec 28, 2024

STEP-HFpEF NT-proBNP Analysis: Greater Benefit with Higher Baseline Cardiac Stress

PICO GLP-1 Receptor Agonists Dec 28, 2024

SURPASS-2

Post-hoc GLP-1 Receptor Agonists Dec 27, 2024

SURPASS Post Hoc Analysis

PICO Semaglutide Dec 27, 2024

Semaglutide + Empagliflozin for NAFLD in T2D

PICO Semaglutide Dec 27, 2024

STEP-HFpEF Pooled Analysis: Semaglutide Improves Symptoms, Function, and Inflammation in Obesity-HFpEF

PICO Semaglutide Dec 27, 2024

Semaglutide and Obesity-Related Heart Failure

Phase 1 GLP-1 Receptor Agonists Dec 27, 2024

Tirzepatide Phase 1 Trial

A phase 1 clamp trial shows tirzepatide improves beta-cell function and insulin sensitivity more than semaglutide, explaining its glucose-lowering. PICO summary and commentary.